Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC
Dr. Wakelee on Single-Agent Immunotherapy in NSCLCПодробнее
Copy of Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLCПодробнее
Dr. Wakelee Discusses Current State of Treatment in NSCLCПодробнее
Dr. Wakelee on Unmet Needs for Immunotherapy in NSCLCПодробнее
Dr. Wakelee on the Rationale for Immunotherapy in NSCLCПодробнее
Dr. Wakelee on Available Treatments Following Tumor Progression in Lung CancerПодробнее
Dr. Farago on the FDA Approval of Pembrolizumab for Lower PD-1 Cutoff NSCLCПодробнее
Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLCПодробнее
Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLCПодробнее
Dr. Lopes on the KEYNOTE-042 Results of Frontline Pembrolizumab in NSCLCПодробнее
Dr. Wakelee on First Trial to Combine Antiangiogenesis Agents With Immunotherapy in NSCLCПодробнее
Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLCПодробнее
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder CancerПодробнее
Dr. Wakelee on Continued Maintenance in Lung CancerПодробнее
Case Overview: Unresectable Stage 3 NSCLCПодробнее
Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLCПодробнее
Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLCПодробнее
Dr. Heather Wakelee Discusses Nintedanib Plus Chemotherapy in NSCLCПодробнее
Dr. Ou on the FDA Approval of Pembrolizumab in SCLCПодробнее
